A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,023actual
Sites
163
Countries
Argentina, Australia, Brazil +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-05 | actual | When the study began enrolling |
| Primary completion | 2026-06-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Cagrilintide
- Drug: Semaglutide
- Drug: Tirzepatide
Primary outcomes
what the primary-completion date above is the date OFChange in Glycated Haemoglobin (HbA1c)
measured From baseline (week 0) to end of treatment (week 60)
Relative Change in Body Weight
measured From baseline (week 0) to end of treatment (week 60)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed